Neftaly Viral Hepatitis B Management

Introduction

Hepatitis B is a viral infection that affects the liver and can lead to chronic disease, liver cirrhosis, and hepatocellular carcinoma. It remains a major global health burden, especially in regions with high endemicity. Neftaly’s Viral Hepatitis B Management Program provides a structured approach to diagnosis, treatment, prevention, and long-term care of patients living with hepatitis B.

---

Objectives

• To ensure early detection and accurate diagnosis of hepatitis B.
• To guide clinical decision-making for treatment and monitoring.
• To prevent transmission through vaccination and education.
• To reduce liver-related complications and mortality.
• To support patients with chronic hepatitis B through integrated care.

---

1. Understanding Hepatitis B

Modes of Transmission

• Perinatal (mother to child at birth)
• Unprotected sexual contact
• Blood transfusion or contact with infected body fluids
• Unsafe injections or needle sharing

Phases of HBV Infection

• Acute infection: May be symptomatic or asymptomatic.
• Chronic infection: Defined by persistence of HBsAg >6 months.

---

2. Screening and Diagnosis

Recommended Populations for Screening

• Pregnant women
• Blood donors
• Individuals from high-prevalence regions
• People living with HIV or hepatitis C
• Household and sexual contacts of HBV-positive individuals

Key Diagnostic Tests

Test	Purpose
HBsAg	Detects current infection
Anti-HBs	Indicates immunity (post-infection or vaccine)
Anti-HBc	Indicates past or ongoing infection
HBeAg / Anti-HBe	Assess infectivity and disease phase
HBV DNA (PCR)	Measures viral load
ALT/AST	Assesses liver inflammation
FibroScan / Biopsy	Evaluates liver fibrosis or cirrhosis

---

3. Management of Acute Hepatitis B

• Supportive care in most cases.
• Monitor for signs of acute liver failure.
• Antiviral therapy in severe cases or immunocompromised patients.

---

4. Management of Chronic Hepatitis B

When to Treat

• HBV DNA >2,000 IU/mL
• Elevated ALT levels
• Evidence of liver fibrosis or cirrhosis
• Co-infection with HIV or HCV
• Family history of liver cancer or cirrhosis

First-Line Antiviral Medications

Medication	Notes
Tenofovir (TDF/TAF)	High barrier to resistance, well tolerated
Entecavir	Effective, low resistance in naïve patients

• Lifelong therapy may be needed.
• Monitor renal function and bone health (especially with tenofovir).

---

5. Monitoring and Follow-Up

For Treated Patients

• HBV DNA levels every 3–6 months
• Liver function tests (ALT/AST)
• Monitor for side effects and adherence

For Untreated Patients

• HBsAg, ALT, HBV DNA every 6–12 months
• Fibrosis assessment as needed

Liver Cancer Surveillance

• Ultrasound and AFP every 6 months in high-risk patients (e.g., cirrhosis, family history of HCC)

---

6. Prevention and Vaccination

Hepatitis B Vaccination

• 3-dose schedule (0, 1, and 6 months)
• Birth dose within 24 hours for newborns
• Protective anti-HBs ≥10 mIU/mL post-vaccination

Other Preventive Measures

• Safe injection practices
• Screening blood donations
• Educating patients on transmission and safe sex

---

7. Special Populations

• Pregnant women: Treat if high viral load; give newborn HBV vaccine + HBIG at birth.
• Co-infection (HIV/HCV): Requires integrated management.
• Children and adolescents: Monitor disease progression; may delay treatment if liver function is stable.

---

8. Neftaly Best Practices

• Integrate HBV care with HIV and maternal health services.
• Use point-of-care testing in low-resource settings.
• Train healthcare workers in hepatitis counseling and stigma reduction.
• Engage communities in awareness and testing campaigns.

---

Conclusion

Managing hepatitis B effectively reduces the burden of liver disease and improves long-term outcomes. Neftaly’s Viral Hepatitis B Management Program empowers healthcare teams to diagnose early, treat appropriately, and support patients with compassion and continuity of care.